{"id":847044,"date":"2025-05-06T07:17:44","date_gmt":"2025-05-06T11:17:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sharps-technology-receives-100k-initial-purchase-order-from-hungarian-vaccine-provider-for-securegard-syringes\/"},"modified":"2025-05-06T07:17:44","modified_gmt":"2025-05-06T11:17:44","slug":"sharps-technology-receives-100k-initial-purchase-order-from-hungarian-vaccine-provider-for-securegard-syringes","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sharps-technology-receives-100k-initial-purchase-order-from-hungarian-vaccine-provider-for-securegard-syringes\/","title":{"rendered":"Sharps Technology Receives ~$100K Initial Purchase Order from Hungarian Vaccine Provider for SecureGard\u2122 Syringes"},"content":{"rendered":"
\n

\n Sharps also received an initial qualification purchase order for DisGard\u2122 single-use Sharps Recovery System<\/em>\n <\/p>\n

\n Company transitions to revenue producing with second purchase order, bringing total recent orders to approximately $500,000 for the quarter <\/em>\n <\/p>\n

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (NASDAQ: \u201cSTSS\u201d and \u201cSTSSW\u201d) (\u201cSharps\u201d), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, announces the receipt of a $100,000 purchase order from a Hungarian vaccine provider. This order supports the recently announced $400,000 SoloGard\u2122 order, which is part of a broader $50 million agreement that was previously announced with a U.S. company and represents the first SecureGard\u2122 order from this Hungary-based company.<\/p>\n

\u201cI am pleased to announce our second significant purchase order to date, bringing our total orders received for Q2 to approximately $500,000,\u201d stated Robert Hayes, Chief Executive Officer of Sharps Technology. \u201cThese latest orders mark the first for our SecureGard and Disgard\u2122 product lines, and we are excited to begin what we anticipate will be a long-term relationship with these customers. With this milestone, Sharps has officially transitioned into a commercial-stage company, which is a pivotal moment in our growth trajectory.\u201d<\/p>\n

In addition to the recent order for SecureGard, Sharps also received an initial qualification order for the\u00a0DisGard Sharps Recovery System – a compact, single-use surgical sharps container designed to support safe, point-of-use disposal in operating rooms and outpatient procedures. The system plays a vital role in surgical inventory recovery by securing small sharps immediately after use, helping healthcare providers reduce loss of surgical instruments and mitigate injury risks.<\/p>\n

Mr. Hayes concluded: \u201cSecureGard, SoloGard, and DisGard are all manufactured at our state-of-the-art facility in Hungary, where we currently maintain inventory levels to meet ongoing and future demand. We are well-positioned to execute on our expanding pipeline of purchase agreements and remain focused on scaling production and fulfillment. We look forward to keeping our shareholders informed as we continue building momentum and delivering on our strategic vision.\u201d<\/p>\n

\n
\n About SecureGard\u00ae<\/sup> Retractable Safety Syringe:<\/u>
\n <\/strong>
\n
The SecureGard Retractable Safety Syringe is a single-use, sterile, disposable hypodermic syringe with a needle attached which is intended for dispensing\/administering fluids in medical practice. The key safety feature, where the clinician retracts the hypodermic needle by manually locking the plunger onto the needle hub, withdrawing the plunger, pulling the needle into the barrel and breaking the plunger, virtually eliminates the accidental clinical reuse of the syringe and accidental needle stick injuries.<\/p>\n

\n Advantages of SecureGard Retractable Needles:<\/strong>\n <\/p>\n